Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

1749results about How to "Useful in treatment" patented technology

Method for treating obstructive sleep disorder includes removing tissue from the base of tongue

InactiveUS7090672B2Stiffening the surrounding tissue structureUseful in treatmentSuture equipmentsHeart valvesThermal energyTongue root
A method for treating obstructive sleep disorders includes accessing the interior of the tongue through an incision made in the skin in the vicinity of the jaw of a patient; advancing an instrument through the incision into the interior of the tongue; and removing an amount of tissue from the interior of the base of the tongue with the instrument. The present invention includes forming a cavity or plurality of channels in the tongue. The cavity may be collapsed using a suture, fastener or bioadhesive. An emplaced suture may be provided to hold the cavity in a collapsed position thereby reducing the degree of obstruction. Additionally, thermal energy may be applied to the tissue surface immediately surrounding the channels to cause thermal damage to the tissue surface, thereby creating hemostasis and stiffening the surrounding tissue structure.
Owner:ARTHROCARE

Cationic antiseptic compositions and methods of use

ActiveUS20060051385A1Reduce eliminateReduce and eliminate clinical signAntibacterial agentsBiocideAmmonium compoundsCetylpyridinium
Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including a cationic antiseptic such as biguanides and bisbiguanides such as chlorhexidine and its various salts including but not limited to the digluconate, diacetate, dimethosulfate, and dilactate salts; polymeric quaternary ammonium compounds such as polyhexamethylenebiguanide; silver and various silver complexes; small molecule quaternary ammonium compounds such as benzalkoium chloride and alkyl substituted derivatives; di-long chain alkyl (C8-C18) quaternary ammonium compounds; cetylpyridinium halides and their derivatives; benzethonium chloride and its alkyl substituted derivatives; and octenidine. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and / or a hydrophilic component. Such compositions provide effective topical antimicrobial activity and are accordingly useful in the treatment and / or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses).
Owner:3M INNOVATIVE PROPERTIES CO

Chemically-modified G-CSF

The present invention provides a chemically-modified protein prepared by binding polyethylene glycol to a polypeptide characterized by being the product of expression by a host cell of an exogenous DNA sequence and substantially having the following amino acid sequence: - - (Het)n - - Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln - - Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg - - Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu - - Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro - - Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly - - Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser - - Gln Ala Leu Gln Leu Ala Cly Cys Leu Ser Gln - - Leu His Ser Gly Leu Phe Leu Tyr Gln GIY Leu - - Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu - - Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val - - Ala Asp Phe Ala Thr Tbr Ile Trp Gln Gln Het - - Glu Glu Leu Gly Het Ala Pro Ala Leu Gln Pro - - Thr Gln Gly Ala Het Pro Ala Phe Ala Ser Ala - - Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala - - Ser His Leu Gln Ser Phe Leu Glu Val Scr Tyr - - Arg Val Leu Arg His Leu Ala Gln Pro - (n = 0 or 1) - The chemically-modified protein according to the present invention has a neutrophils-increasing activity much more lasted than that of the intact human G-CSF, enabling fewer numbers of administration with a lower dose.
Owner:KIRIN AMGEN

Antiseptic compositions and methods of use

InactiveUS20060051384A1Reduce and eliminateReduce and eliminate clinical signAntibacterial agentsBiocideCarboxylateMucosal tissue
Antimicrobial compositions, especially those useful when applied topically to tissue, such as mucosal tissues (i.e., mucous membranes), that include an antimicrobial selected from the group consisting of peroxides, C6-C14 alkyl carboxylic acids, C6-C14 alkyl carboxylate ester carboxylic acids, C8-C22 mono- or polyunsaturated carboxylic acids, and antimicrobial natural oils. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and / or a hydrophilic component. Such compositions provide effective topical antimicrobial activity and are accordingly useful in the treatment and / or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses).
Owner:3M INNOVATIVE PROPERTIES CO

Novel compounds

A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.
Owner:MITSUBISHI TANABE PHARMA CORP

Wireless electric modulation of sympathetic nervous system

A method for the treatment of obesity or other disorders, by wireless electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by wirelessly stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using a wireless electrode inductively coupled with a radiofrequency field. The source of radiofrequency energy may be internal or external to the patient. This nerve activation can result in reduced food intake and increased energy expenditure.
Owner:ADVANCED NEUROMODULATION SYST INC

Phenolic antiseptic compositions and methods of use

ActiveUS20060052452A1Reduce eliminateReduce and eliminate clinical signAntibacterial agentsBiocideDiphenyl etherSURFACTANT BLEND
Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including an antiseptic selected from the group consisting of halogenated phenols, bisphenols, diphenyl ethers, anilides and derivatives thereof, and combinations thereof. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and / or a hydrophilic component. Such compositions provide effective topical antimicrobial activity and are accordingly useful in the treatment and / or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses).
Owner:3M INNOVATIVE PROPERTIES CO

Electric modulation of sympathetic nervous system

A method for the treatment of obesity or other disorders, by electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by electrically stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an implantable pulse generator. This nerve activation can result in reduced food intake and increased energy expenditure. Reduced food intake may occur through a variety of mechanisms that reduce appetite and cause satiety. Increased adrenal gland hormone levels will result in increased energy expenditure. Fat and carbohydrate metabolism, which are also increased by sympathetic nerve activation, will accompany the increased energy expenditure.
Owner:ADVANCED NEUROMODULATION SYST INC

Indazole compounds, compositions thereof and methods of treatment therewith

This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.
Owner:SIGNAL PHARMA LLC

Novel therapeutic compounds

Disclosed herein are novel compounds of Formula (I),wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases as well as proliferative disorders such as cancer.
Owner:ABBVIE INC

Pyrazolopyrimidines as protein kinase inhibitors

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of protein and / or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions. The invention also relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.
Owner:MERCK SHARP & DOHME LLC

Method for screening and treating patients at risk of medical disorders

Method for screening patients to predict which patients at risk of a medical disorder, such as morbid obesity, gastrointestinal problems, or gastroesophageal problems, will be responders, and conversely, which patients will not, to achieve a favorable outcome from therapy for that disorder. This method supports an intervention strategy for patients having weight or gastrointestinal problems that will cut health costs. It enables patients and care-givers alike to more efficiently use their time, efforts and resources by enabling an early selection of an appropriate treatment modality for a given patient. Its application also extends to other implantable medical devices and therapies using them.
Owner:TRANSNEURONIX INC

Thienopyridones as AMPK activators for the treatment of diabetes and obesity

The present invention relates to compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, and obesity.
Owner:ABBVIE INC

Derivatives of 4- or 5-aminosalicylic acid

InactiveUS20060270635A1Less readily absorbedEasily reach colonBiocidePhosphorous compound active ingredientsThioester synthesisSalicylic acid
The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention / treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention / treatment of colon cancer.
Owner:ANTIBE THERAPEUTICS INC

Morphinan-derivatives for treating diabetes and related disorders

The invention relates to a morphinan-derivative that targets NMDA receptors on pancreatic islets and has the general formula (I)whereinR1 is selected from —OH, —CO2H, —R0, —OR0, —OC(═O)R0, —OC(═O)OR0 or —OC(═O)NHR0; and R2 is selected from —H, —R0, —C(═O)R0, —C(═O)OR0, —C(═O)NHR0 or —C(═NH)—NH—C(═NH)—NH2; wherein R0 is in each case independently selected from —C1-C6-alkyl, -aryl, -heteroaryl, —C1-C6-alkyl-aryl or —C1-C6-alkyl-heteroaryl, in each case independently unsubstituted or substituted;or its physiologically acceptable salt and / or stereoisomer, including mixtures thereof in all ratios, for use in the treatment of a disease or condition, where the disease or condition is insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, obesity, and / or diabetic nephropathy.
Owner:DEUTE DIABETES FORSCHUNGSGES

Method and apparatus for connective tissue treatment

The invention relates to methods and apparatus for therapeutically treating connective tissue or increasing vascularization in tissue using ultrasound. More particularly, the present invention relates to methods and apparatus which use ultrasound to stimulate growth or healing, or to treating pathologies, of connective tissue, or to increase vascularization in ischaemic or grafted tissue using ultrasound.
Owner:EXOGEN

Libraries of peptide conjugates and methods for making them

The invention relates to peptide conjugates including at least one turn inducer wherein the turn inducer comprises a 5-7 membered saturated or unsaturated nitrogen containing heterocyclic ring and methods of making the peptides. Libraries of these peptides, methods of making the libraries are also described and methods of screening the libraries for therapeutic activity are also described.
Owner:XENOME

Combination of probiotics

The invention relates to a probiotic combination comprising different combinations of lactobacilli. propionic acid bacteria and / or bifidobacteria. The probiotics are preferably combined with a suitable prebiotic to form a synbiotic. The combination of the invention can be consumed as such or combined with a suitable foodstuff or pharmaceutical product, and it is therapeutically useful for example for stimulating the immune system and for general health improvement.
Owner:CHR HANSEN AS

Nitrogenated heterocyclic derivative , and pharmaceutical agent comprising the derivative as active ingredient

The compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof specifically binds CCR5, so it is useful for preventing and / or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection diabetes cancer metastasis and so on.Wherein all symbols in formula are as defined in the specification
Owner:ONO PHARMA CO LTD

Topical Antiviral Formulations

The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (N(t)RTIs), preferably [2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), or a physiologically functional derivative thereof, suitable for topical application and their use in the prevention of HIV infections.
Owner:EASTERN VIRGINIA MEDICAL SCHOOL +1

Method for reducing the immunogenicity of antibody variable domains

A unique method is disclosed for identifying and replacing immunoglobulin surface amino acid residues which converts the antigenicity of a first mammalian species to that of a second mammalian species. The method will simultaneously change immunogenicity and strictly preserve ligind binding properties. The judicious replacement of exterior amino acid residues has no effect on the ligind binding properties but greatly alters immunogenicity.
Owner:DEPT OF HEALTH & HUMAN SERVICES US SEC THE +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products